网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
PD-L1在非小细胞肺癌中的表达及其临床意义
作者:熊磊  刘小龙  徐杨  罗立国  李德闽  申翼 
单位:东部战区总医院 心胸外科, 江苏 南京 210002
关键词:程序性死亡受体-配体1 非小细胞肺癌 无进展生存时间 免疫组化 
分类号:R734.2
出版年·卷·期(页码):2020·48·第九期(1169-1173)
摘要:

目的:探讨程序性死亡受体-配体1(PD-L1)在晚期非小细胞肺癌中的表达及其预后价值。方法:收集70例非小细胞肺癌患者肿瘤组织,通过免疫组化检测肿瘤组织中PD-L1的表达。Kaplan-Meier生存曲线及多变量Cox回归模型分析PD-L1表达与患者预后的关系。结果:70例肺癌标本中有36例(51.4%)PD-L1高表达。肿瘤细胞PD-L1高表达的患者预后较差,无进展生存时间较短[14个月(95% CI:12.06~17.45)vs 20个月(95% CI:17.05~23.26),P=0.007]。结论:PD-L1在国内非小细胞肺癌中也呈高表达,同时其表达水平与非小细胞肺癌患者的预后密切相关,可能是非小细胞肺癌的独立预后指标。

Objective: To investigate the expression and the prognostic value of programmed cell death-ligand 1(PD-L1) protein in human non-small cell lung cancer(NSCLC).Methods: Tumor tissues from 70 lung cancer patients were analyzed in this study and PD-L1 expressions in tumor tissue were detected by immunohistochemistry. Kaplan-Meier survival curves and multivariate Cox regression model were employedto analyze relationship between the expression of PD-L1 and the prognosis of the patients. Results: The result showed that PD-L1 was highly expressed in 36 (51.4%) of 70 lung cancer specimens. Patients with high PD-L1 expression in NSCLC had a poor prognosis with shorter progression free survival time [14 months (95% CI:12.06-17.45) vs.20 months (95% CI:17.05-23.26), P=0.007].Conclusion: This study suggests that PD-L1 expression correlates closely with prognosis of patients with NSCLC and it might be an independent prognostic marker for NSCLC.

参考文献:

[1] SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2018[J].CA Cancer J Clin,2018,68(1):7-30.
[2] 周婉婉,梁冰,王效静,等.非小细胞肺癌患者外周血h TERT mRNA水平检测的临床意义[J].东南大学学报(医学版),2017,36(2):217-221.
[3] TANVETYANON T,CREELAN B C,CHIAPPORI A A.Current clinical application of genomic and proteomic profiling in non-small-cell lung cancer[J].Cancer Control,2014,21(1):32-39.
[4] RUIZ R,HUNIS B,RAEZ L E.Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines[J].Curr Oncol Rep,2014,16(9):1-10.
[5] MARRONE K A,BRAHMER J R.Immune checkpoint therapy in non-small cell lung cancer[J].Cancer J,2016,22(2):81-91.
[6] RIBAS A.Tumor immunotherapy directed at PD-1[J].New Eng J Med,2012,366(26):2517-2519.
[7] RIZVI N A,MAZIÈRES J,PLANCHARDD,et al.Activity and safety of nivolumab,an anti-PD-1 immune checkpoint inhibitor,for patients with advanced,refractory squamous non-small-cell lung cancer (CheckMate 063):a phase 2,single-arm trial[J].Lancet Oncol,2015,16(3):257-265.
[8] GETTINGER S N,HORN L,GANDHI L,et al.Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody,BMS-936558,ONO-4538) in patients with previously treated advanced non-small-cell lung cancer[J].J Clin Oncol 2015,33(18):2004-2012.
[9] RECK M,POPAT S,REINMUTH N,et al.Metastatic non-small-cell lung cancer (NSCLC):ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2014,25(Suppl 3):iii27-39.
[10] OHAEGBULAM K C,ASSAL A,LAZAR-MOLNAR E,et al.Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway[J].TrendsMolec Med,2015,21(1):24-33.
[11] 李晓雷,徐俊,胡欣,等.多中心多学科治疗模式下对局部晚期非小细胞肺癌患者的新辅助化疗疗效及对预后影响的临床研究[J].东南大学学报(医学版),2018,37(4):667-672.
[12] CHEN S,WANG R X,LIU Y,et al.PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy[J].Int J Cancer,2017,140(6):1384-1395.
[13] CALDERARO J,ROUSSEAU B,AMADDEO G,et al.Programmed death ligand 1 expression in hepatocellular carcinoma:relationship with clinical and pathological features[J].Hepatol,2016,64(6):2038-2046.
[14] WEBB J R,MILNE K,NELSON B H.PD-1 and CD103 are widely coexpressed on prognostically favorable intraepithelial CD8 T cells in human ovarian cancer[J].Cancer Immunol Res,2015,3(8):926-935.
[15] ETO S,YOSHIKAWA K,NISHI M,et al.Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection[J].Gastric Cancer,2016,19(2):466-471.
[16] KIM M Y,KOH J,KIM S,et al.Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma:comparison with tumor-infiltrating T cells and the status of oncogenic drivers[J].Lung Cancer,2015,88(1):24-33.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 399332 位访问者


 ©《现代医学》编辑部
联系电话:025-83272481;83272479
电子邮件: xdyx@pub.seu.edu.cn

苏ICP备09058541